[Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy].
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000549:Ambenonium Chloride / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004491:Edrophonium / Q000627:therapeutic use; D004576:Electromyography; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D009388:Neostigmine / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012129:Respiratory Function Tests; D013934:Thymectomy; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D009388:Neostigmine; D000549:Ambenonium Chloride; D004491:Edrophonium; D011729:Pyridostigmine Bromide
Myasthenia gravis pseudoparalytica. Klinik, Pathogenese, Therapie.